Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Leuprolide Acetate

FDA-approved product (solution, subcutaneous), marketed as Eligard Kit, Fensolvi Kit, Leuprolide Acetate and 8 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Leuprolide Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Central precocious puberty
  • Metastatic prostate cancer
  • Neoplasm
  • Precocious puberty
  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Gonadotropin releasing hormone analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli59.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Leuprolide Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Leuprolide Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Polycystic Ovary Syndrome (PCOS) and Sleep Apnea

    NCT00203996 · start 2003-09

    Registered record
    Registry ID
    NCT00203996
    Conditions
    Polycystic Ovary Syndrome; Obstructive Sleep Apnea
    Interventions
    continuous positive airway pressure (CPAP); depot leuprolide plus estrogen/progestin replacement; pioglitazone; REM frag; SWS supp
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2003-09
    Completion
    2008-06
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovary Syndrome; Obstructive Sleep Apnea
    Interventioncontinuous positive airway pressure (CPAP); depot leuprolide plus estrogen/progestin replacement; pioglitazone; REM frag +1 more
    PhasePhase 4
    Registry statusTerminated

  • ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation

    NCT00063310 · start 2003-03

    Registered record
    Registry ID
    NCT00063310
    Conditions
    Alzheimer Disease
    Interventions
    Leuprolide acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-03
    Completion
    2006-02
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    InterventionLeuprolide acetate
    PhasePhase 2
    Registry statusCompleted

  • Lupron Sex Offender Therapy

    NCT00220350 · start 2001-10

    Registered record
    Registry ID
    NCT00220350
    Conditions
    Pedophilia
    Interventions
    leuprolide acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2001-10
    Completion
    2005-08
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPedophilia
    Interventionleuprolide acetate
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • A Treatment Study for Premenstrual Syndrome (PMS)

    NCT00001259 · start 1992-08-11

    Registered record
    Registry ID
    NCT00001259
    Conditions
    Premenstrual Syndrome; Menstruation Disturbances
    Interventions
    Leuprolide; Estradiol Patches; Progesterone; Placebo patch; Placebo injection; Placebo suppository
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1992-08-11
    Completion
    2020-02-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPremenstrual Syndrome; Menstruation Disturbances
    InterventionLeuprolide; Estradiol Patches; Progesterone; Placebo patch +2 more
    PhasePhase 1
    Registry statusCompleted

  • A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma

    NCT00001266 · start 1990-10

    Registered record
    Registry ID
    NCT00001266
    Conditions
    Prostatic Neoplasm
    Interventions
    Suramin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1990-10
    Completion
    2003-08
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasm
    InterventionSuramin
    PhasePhase 2
    Registry statusCompleted